Clindamycin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Clindamycin: From Antibacterial Use to Punctate Epithelial Keratoconjunctivitis
One-Sentence Summary
Clindamycin is a lincosamide antibacterial that inhibits bacterial protein synthesis. The registration data supplied does not state its approved indications. The TxGNN model predicts it may be effective for punctate epithelial keratoconjunctivitis. Currently 0 clinical trials and 0 publications support this specific prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration data (clindamycin is a lincosamide antibacterial) |
| Predicted New Indication | Punctate epithelial keratoconjunctivitis |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 5 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Clindamycin is known to be a lincosamide that inhibits bacterial protein synthesis, so its established efficacy lies in bacterial infections.
Punctate epithelial keratoconjunctivitis is usually viral or toxic/inflammatory, so a direct antibacterial mechanism is not evident. The prediction may reflect indirect links in the knowledge graph rather than a clear pharmacological rationale. A high TxGNN score of 99.97% is a model output and does not by itself show that the drug works. Without trials, literature or MOA data, the mechanistic case for this indication is weak.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| P/20.1.6/63 | Dalacin T Solution | Solution | Not stated in registration data |
| F/20.1.1/169 | Dalacin C 600Mg | Injection | Not stated in registration data |
| 42/13.11/0441 | Clindoxyl | Geo (as recorded) | Not stated in registration data |
| A.682 | Daraprim | Tablet | Not stated in registration data |
| 49/13.12/0499 | Treclin Gel | Gel | Not stated in registration data |
Notes:
- Essential Medicines List (EML) status is not available in the Evidence Pack.
- Daraprim is normally a pyrimethamine product. Please verify that this registration is correctly linked to clindamycin.
- No ophthalmic formulation appears among the registrations.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is model-only (L5), with no trials or literature, and no plausible antibacterial mechanism for a mainly viral or toxic/inflammatory condition. Safety data are also missing, and none of the five registered products is an ophthalmic formulation. The other top-ranked predictions in this pack are also on Hold. Where any literature exists, it concerns other diseases or veterinary infections.
To proceed, the following is needed:
- SAHPRA Professional Information (warnings and contraindications), which blocks any safety screening
- Detailed mechanism of action (MOA) data from DrugBank
- Any clinical or preclinical evidence in punctate epithelial keratoconjunctivitis
- Route compatibility assessment, since no ophthalmic product is registered
- Verification of the Daraprim registration link
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.